Alto Neuroscience ANRO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Direct external program expenses: by Product | ||||||
| ALTO-100 | $1.76M+14.5% | $1.54M-9.6% | $1.71M+13.6% | $1.5M+33.5% | $1.12M+97.5% | |
| ALTO-101 | $5.36M+210% | $1.73M+24.5% | $1.39M+55.4% | $893K-7.8% | $969K+920% | |
| ALTO-203 | $6K-90.9% | $66K-69.7% | $218K-63.6% | $599K-18.7% | $737K-34.8% | |
| ALTO-207 | $4.14M+362% | $896K+160% | $345K-3.6% | $358K— | $0— | |
| ALTO-300 | $1.51M+0.6% | $1.5M+7.3% | $1.4M+114% | $653K-29.2% | $922K-47.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alto Neuroscience break its business down?
- Alto Neuroscience (ANRO) reports direct external program expenses: by product across 5 parts — ALTO-100, ALTO-101, ALTO-203, ALTO-207 and ALTO-300. Each is extracted from the segment footnotes and tracked over time.
- Where does Alto Neuroscience's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alto Neuroscience's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.